Current clinical trials in renal cell carcinoma

Mitchell H. Sokoloff, Siamak Daneshmand, Christopher Ryan

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    The treatment of renal cell carcinoma remains primarily surgical. Consequently, it is not surprising that urologists have been active in the design and operation of clinical trials for patients with kidney cancer. Currently, clinical trial efforts of the urologic community are focused on the adjuvant setting in patients undergoing nephrectomy at high risk for recurrence or metastasis. As newer agents become available and are applied earlier during the course of the disease, the involvement of urologists in clinical trials in renal cell carcinoma will increase. This review highlights several key trials currently available for patients with kidney cancer.

    Original languageEnglish (US)
    Pages (from-to)289-292
    Number of pages4
    JournalUrologic Oncology: Seminars and Original Investigations
    Volume23
    Issue number4
    DOIs
    StatePublished - Jul 2005

    Fingerprint

    Renal Cell Carcinoma
    Kidney Neoplasms
    Clinical Trials
    Nephrectomy
    Neoplasm Metastasis
    Recurrence
    Urologists
    Therapeutics

    Keywords

    • Clinical trials
    • Kidney cancer
    • Nephrectomy
    • Targeted therapy

    ASJC Scopus subject areas

    • Oncology
    • Urology

    Cite this

    Current clinical trials in renal cell carcinoma. / Sokoloff, Mitchell H.; Daneshmand, Siamak; Ryan, Christopher.

    In: Urologic Oncology: Seminars and Original Investigations, Vol. 23, No. 4, 07.2005, p. 289-292.

    Research output: Contribution to journalArticle

    Sokoloff, Mitchell H. ; Daneshmand, Siamak ; Ryan, Christopher. / Current clinical trials in renal cell carcinoma. In: Urologic Oncology: Seminars and Original Investigations. 2005 ; Vol. 23, No. 4. pp. 289-292.
    @article{6e38bfe4fdb245ccabcf60120bbc702e,
    title = "Current clinical trials in renal cell carcinoma",
    abstract = "The treatment of renal cell carcinoma remains primarily surgical. Consequently, it is not surprising that urologists have been active in the design and operation of clinical trials for patients with kidney cancer. Currently, clinical trial efforts of the urologic community are focused on the adjuvant setting in patients undergoing nephrectomy at high risk for recurrence or metastasis. As newer agents become available and are applied earlier during the course of the disease, the involvement of urologists in clinical trials in renal cell carcinoma will increase. This review highlights several key trials currently available for patients with kidney cancer.",
    keywords = "Clinical trials, Kidney cancer, Nephrectomy, Targeted therapy",
    author = "Sokoloff, {Mitchell H.} and Siamak Daneshmand and Christopher Ryan",
    year = "2005",
    month = "7",
    doi = "10.1016/j.urolonc.2005.05.007",
    language = "English (US)",
    volume = "23",
    pages = "289--292",
    journal = "Urologic Oncology: Seminars and Original Investigations",
    issn = "1078-1439",
    publisher = "Elsevier Inc.",
    number = "4",

    }

    TY - JOUR

    T1 - Current clinical trials in renal cell carcinoma

    AU - Sokoloff, Mitchell H.

    AU - Daneshmand, Siamak

    AU - Ryan, Christopher

    PY - 2005/7

    Y1 - 2005/7

    N2 - The treatment of renal cell carcinoma remains primarily surgical. Consequently, it is not surprising that urologists have been active in the design and operation of clinical trials for patients with kidney cancer. Currently, clinical trial efforts of the urologic community are focused on the adjuvant setting in patients undergoing nephrectomy at high risk for recurrence or metastasis. As newer agents become available and are applied earlier during the course of the disease, the involvement of urologists in clinical trials in renal cell carcinoma will increase. This review highlights several key trials currently available for patients with kidney cancer.

    AB - The treatment of renal cell carcinoma remains primarily surgical. Consequently, it is not surprising that urologists have been active in the design and operation of clinical trials for patients with kidney cancer. Currently, clinical trial efforts of the urologic community are focused on the adjuvant setting in patients undergoing nephrectomy at high risk for recurrence or metastasis. As newer agents become available and are applied earlier during the course of the disease, the involvement of urologists in clinical trials in renal cell carcinoma will increase. This review highlights several key trials currently available for patients with kidney cancer.

    KW - Clinical trials

    KW - Kidney cancer

    KW - Nephrectomy

    KW - Targeted therapy

    UR - http://www.scopus.com/inward/record.url?scp=21844436790&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=21844436790&partnerID=8YFLogxK

    U2 - 10.1016/j.urolonc.2005.05.007

    DO - 10.1016/j.urolonc.2005.05.007

    M3 - Article

    C2 - 16018946

    AN - SCOPUS:21844436790

    VL - 23

    SP - 289

    EP - 292

    JO - Urologic Oncology: Seminars and Original Investigations

    JF - Urologic Oncology: Seminars and Original Investigations

    SN - 1078-1439

    IS - 4

    ER -